Dr M Rafferty
No more applications being accepted
Funded PhD Project (Students Worldwide)
About the Project
We are looking for an Early Stage Researcher (PhD Student) to join OncoMark (www.oncomark.com). Our offices and laboratory are based at NovaUCD, which is a Technology Transfer and Innovation Centre at University College Dublin, Ireland (www.ucd.ie/nova). The successful candidate will be employed by OncoMark, but registered for their PhD by UCD under Prof. William Gallagher.
OncoMark is currently involved in a number of EU funded projects, including a new pan-European academic/private sector research training network project called MEL-PLEX –Identifying and validating a panel of master transcriptional regulators in advanced melanoma, using a systems transcriptomics and histology approach (Project 12). The project will be carried out in collaboration with Prof. Walter Kolch (University College Dublin, UCD) and Prof. Patrizia Agostinis (University of Leuven, KUL ,Belgium).
Initially, the candidate will be seconded to UCD in Ireland, for six months to collate specific melanoma cohort data. Then, using bioinformatics and systems transcription tools such as ARACNE, will identify key network targets that regulate transcription during melanoma progression. In Oncomark, the candidate will validate the data using tissue analysis techniques (WB, IHC) and process the data using advanced digital image analysis, statistical analysis and data driven systems modelling. During a 3 month secondment to KUL (Belgium), the candidate will gain experience with pathologists, manually assessing the IHC stains and determining scores.
Funding Notes
Eligibility and Candidate requirements:
• IMPORTANT: At the time of recruitment, the candidate must not have resided or carried out their main activity (work, studies, etc.) in the country of their recruiting organisation for more than 12 months in the 3 years immediately prior to start of the project. Candidates can be of any nationality, but are required to undertake transnational mobility.
• Candidates should ideally possess a Master’s degree in a relevant academic field.
• Experience/techniques (desirable);
Cancer Research (particularly melanoma)/Immunohistochemical assays/Molecular biological techniques (western blotting/histology/cell culture)
Good Computer/Bioinformatic/Biostatistics skills, an advantage
References
Application process:
• A full CV, a covering letter including a description of previous research experiences and contact details or recommendation letters of two 2 referees;
• Submit the documentation to melplexETN@rcsi.ie writing the code of the selected project(s) on the title field (i.e Project 12) by Friday, January 30th, 2015 at 5 pm (GMT). Please note that applications failing to contain the requested documentation or which do not indicate the preferred project(s)* WILL NOT be considered in this competition.
• Contract: 3 years from 01/05/2015. Salary will be competitive and subject to experience.
Overview of the European Training Network programme:
The programme will be funded through the Horizon 2020 Marie Skłodowska Curie Actions. It involves 15 projects and applicants can select up to three (3) preferred projects*. To obtain more details please visit
http://www.systemsmedicineireland.ie/research/melanoma/mel-plex/
In the absence of personalised and optimised treatment options, great numbers of cancer patients suffer from inefficient therapies. Malignant melanoma exemplifies a largely chemotherapy-resistant, highly heterogeneous and aggressive cancer. Novel treatment options for personalised, patient-tailored melanoma therapies can now be explored or developed through newly emerging and innovative research disciplines that go significantly beyond the current state-of-the-art, such as translational cancer systems biology and cancer systems medicine.
The main objectives are to (i) achieve an unmatched depth of molecular and mechanistic disease understanding, (ii) exploit this knowledge to develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iii) provide superior and clinically relevant tools and biomarker signatures for personalising and optimising melanoma therapy.
All projects comprise experimental approaches as well as advanced data analysis or systems modelling approaches.
For a full list of all 15 projects please visit
http://www.systemsmedicineireland.ie/research/melanoma/mel-plex/
OncoMark Ltd is an Irish private company centred on the development and clinical application of cancer biomarkers. OncoMark was spun out of UCD and the overall company strategy is to develop and validate protein biomarker panels, using advanced histology technologies, specifically to develop predictive tests for patient outcome and stratification with cancer treatment. The company conducts in house research and development in this arena and has developed key expertise in TMA construction, digital slide scanning, automated image analysis and statistics. The company has also developed a proprietary in-house image analysis toolkit for assessment of IHC based markers at the subcellular compartmental level.
Continue with Facebook
